-
British Journal of Haematology Sep 1993
Topics: Blood Cell Count; Blood Platelets; Danazol; Humans; Myelodysplastic Syndromes
PubMed: 8251401
DOI: 10.1111/j.1365-2141.1993.tb08681.x -
The Journal of Allergy and Clinical... Feb 1983
Topics: Angioedema; Danazol; Female; Gonadal Steroid Hormones; Humans; Male; Pregnadienes; Pregnancy
PubMed: 6822696
DOI: 10.1016/0091-6749(83)90109-4 -
Annals of Internal Medicine Jan 1980
Topics: Adult; Creatine Kinase; Danazol; Female; Humans; Hypothyroidism; Pregnadienes; Thyroxine; Thyroxine-Binding Proteins
PubMed: 6766050
DOI: 10.7326/0003-4819-92-1-133_2 -
Nihon Rinsho. Japanese Journal of... Jan 2001
Review
Topics: Danazol; Endometriosis; Estrogen Antagonists; Female; Humans; Receptors, Androgen
PubMed: 11235153
DOI: No ID Found -
European Journal of Haematology Oct 198720 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%),... (Clinical Trial)
Clinical Trial
20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.
Topics: Clinical Trials as Topic; Danazol; Female; Humans; Male; Myelodysplastic Syndromes; Pregnadienes
PubMed: 3319676
DOI: 10.1111/j.1600-0609.1987.tb00780.x -
Journal of the Royal Society of Medicine Jun 1993
Topics: Abdominal Pain; Chronic Disease; Danazol; Female; Humans; Middle Aged; Pancreatitis
PubMed: 8315635
DOI: 10.1177/014107689308600618 -
South African Medical Journal =... Oct 1980Thirty-six women with endometriosis externa were treated with danazol (Ladogar; Winthrop Laboratories, Division of Sterling Drug (SA) (Pty) Ltd) for 6 months. In 15... (Clinical Trial)
Clinical Trial
Thirty-six women with endometriosis externa were treated with danazol (Ladogar; Winthrop Laboratories, Division of Sterling Drug (SA) (Pty) Ltd) for 6 months. In 15 cases treatment was combined with conservative surgery. Of these patients 34 presented with the complaint of infertility. The results were evaluated by means of repeat laparoscopy and biopsy. Of 21 patients treated with danazol only 9 (42,9%) were completely healed, and 10 (47,6%) showed a good response, giving an overall response of 90,5% and a corrected conception rate of 52,9%. Of the 15 patients who were treated with danazol combined with conservative surgery, 9 (60%) have completely healed, and 3 had a recurrence of endometriosis. This group had a corrected pregnancy rate of 30,8%. The majority of conceptions (61,5%) occurred during the first 6 months after treatment, 92,3% within the 1st year and 1 a year after conclusion of treatment. Of the 13 conceptions, 11 were successful, 1 ended in an abortion and 1 in an ectopic pregnancy, and 1 small-for-gestational-age infant was delivered.
Topics: Adult; Clinical Trials as Topic; Danazol; Endometriosis; Female; Humans; Infertility, Female; Pregnadienes; Uterine Neoplasms
PubMed: 6999637
DOI: No ID Found -
American Journal of Obstetrics and... Dec 1975Danazol, an antigonadotropic agent, was administered in a dosage of 800 mg. daily for six months to 32 patients with pelvic endometriosis. Twenty-eight patients (87.5...
Danazol, an antigonadotropic agent, was administered in a dosage of 800 mg. daily for six months to 32 patients with pelvic endometriosis. Twenty-eight patients (87.5 per cent) were found to have a marked improvement of both clinical and subjective symptoms of endometriosis. Furthermore, Danazol was found to be effective in three patients with chronic cystic mastitis and one patient with fibrocystic disease. There was no change in uterine size in two patients with uterine adenomyosis and one patient with uterine myomas during the treatment period. Danazol was ineffective in relieving the symptoms of the menopausal syndrome in one patient. The main side effects of Danazol treatment were weight gain and water retention which were maximal at four months of treatment and then decreased. Other side effects such as acne, oiliness of skin, and voice change were rare in this series. Danazol therapy was found to be very effective in this study for the treatment of pelvic endometriosis, and the drug was well tolerated by the patients.
Topics: Body Weight; Cysts; Danazol; Endometriosis; Female; Humans; Mastitis; Middle Aged; Pelvic Neoplasms; Pregnadienes; Pregnancy
PubMed: 1200068
DOI: 10.1016/0002-9378(75)90499-8 -
The Journal of Reproductive Medicine Jan 1990Approximately 90% of women experience some symptoms of the premenstrual syndrome (PMS); in up to 40% of cases the symptoms are moderate to severe. The signs and symptoms... (Review)
Review
Approximately 90% of women experience some symptoms of the premenstrual syndrome (PMS); in up to 40% of cases the symptoms are moderate to severe. The signs and symptoms of PMS usually wax and wane according to a four-phase temporal pattern. Within this overall schema there are a number of PMS subtypes. PMS typically manifests before the age of 30 and rarely resolves spontaneously. While genetic factors may play a role in the development of PMS, other epidemiologic factors do not seem to be involved. Various pathophysiologic mechanisms have been proposed as causing PMS. They are an estrogen/progesterone imbalance, prolactin abnormalities, fluid retention, abnormal production of certain prostaglandins, hypoglycemia, pyridoxine deficiency and shifting levels of endorphins. However, the role of these factors in the etiology of PMS has not been established definitively; thus, treatment remains largely empiric. The author's experience with the use of Danocrine (danazol) on 21 patients with PMS suggests that this synthetic steroid, when used in conjunction with nonpharmacologic treatment options, relieves the symptoms of PMS in up to 85% of patients. Women whose PMS is characterized primarily by mastalgia appear to respond most favorably to treatment; danazol is not recommended for women with primary depression or anxiety symptomatology.
Topics: Adult; Danazol; Female; Humans; Pregnadienes; Premenstrual Syndrome
PubMed: 2404119
DOI: No ID Found -
The Journal of Reproductive Medicine Jun 1991Of 131 women with hormonally related migraines unresponsive to standard medication, 67 (51.1%) noted profound relief after a 12-month, phased study using danazol for... (Clinical Trial)
Clinical Trial
Of 131 women with hormonally related migraines unresponsive to standard medication, 67 (51.1%) noted profound relief after a 12-month, phased study using danazol for migraine prevention. The first three phases consisted of two-month cycles: dietary control and acetazolamide, the addition of danazol and danazol discontinuation. Eighty-three women (63.36%) reported control of their hormonal migraines while using danazol. In phase IV, 81 women whose headaches were controlled by danazol restarted danazol for an additional six months. Sixty-seven (82.7%) reported continued success with this medication. Danazol proved highly successful in the control of women's cyclic migraine. Its effectiveness remained consistent throughout the treatment course. In the prophylactic treatment of women's hormonal migraine, 400 mg of danazol administered daily for 25 days each month can prove effective when standard medical therapy fails. Furthermore, the response to danazol supported the concept that hormonal migraine should be treated as a distinct clinical entity.
Topics: Acetazolamide; Adult; Combined Modality Therapy; Danazol; Drug Therapy, Combination; Female; Humans; Menstrual Cycle; Middle Aged; Migraine Disorders
PubMed: 1865397
DOI: No ID Found